Abstract:

In this study, we aimed at examining the demographic characteristics of patients diagnosed with cataractic malignant melanoma in our center, the treatments and responses they received. Tools and Methods: In July 2012–June 2022 at our oncology clinic 45 patients diagnosed with malignant melanoma were retrospective scanned and a total of 32 patients were included in the study. Clinical and demographic data were presented with descriptive analysis. Categorical and numerical variables are given as number and percentage (n, percentage). PFS and OS are calculated using the Kaplan-Meier method. Results: 19 of the patients involved in the study (59.4%) were men and 13 were women (40.6%) The patient’s average age was 65 (38-86). Primary tumor was settled in the body in 13(40.6) patients respectively, 6(18.8) patients in the body and 13(40.6) patients in the head-to-head. 8(25%) of patients had BRAF mutation. 22 of the patients (68.7%) were in the metastatic stage. Progressive survival (PFS) in patients in the metastatic stage 5.2 months (std. err:1.21, 95%CI:2.86-7.59) while median general survival (OS) 23.9 (std. err:3.65, 95% was the month of the month (16.8-31.11). As a result, cataractic malignant melanoma is the fifth most common cancer. In advanced stages, mortality rates are very high and multidisciplinary follow-up is needed.

Keywords: